ArticleBMC infectious diseases2026
Antimicrobial resistance patterns of Ureaplasma and Mycoplasma in urethritis: a six-year retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo describe the distribution of Ureaplasma spp. and Mycoplasma spp. detections and antimicrobial susceptibility patterns among symptomatic patients evaluated for urogenital infection at a tertiary care center in Turkey over six years (2019-2024).
methodsThis retrospective study included adults who underwent laboratory testing for Ureaplasma spp. and Mycoplasma spp. due to urogenital infection symptoms. Clinical specimens included first-void urine samples and urethral or cervical swabs. Detection was performed using a commercial multiplex Polymerase Chain Reaction (PCR) assay, with culture-based confirmation and antimicrobial susceptibility testing.
resultsA total of 525 patients with laboratory-detected Ureaplasma spp. and/or Mycoplasma spp. were analyzed. Ureaplasma spp. were detected in 92.6% of cases, Mycoplasma spp. in 1.5%, and dual detection in 5.9% of cases. The median age was 29 years (range: 17-83 years), and 69.0% were male. Urethral discharge (42.9%) and unprotected sexual contact (67.0%) were the most common symptoms. Coexisting sexually transmitted infections (STIs) were recorded, with Human Papilloma Virus (HPV) being the most frequently reported. Antimicrobial susceptibility testing revealed high resistance to fluoroquinolones, particularly ciprofloxacin (79.3% in Ureaplasma spp. and 56.4% in Mycoplasma spp.). Tetracycline susceptibility was observed in 75.2% and 71.8% of isolates, respectively, whereas josamycin showed the highest susceptibility rates (96.1% and 82.1%). Antibiotic therapy was prescribed in 85.1% of patients, mostly doxycycline-based therapy. Follow-up evaluation was performed in 48.2% of cases.
conclusionIn this six-year, single-center cohort of symptomatic patients, Ureaplasma spp. was the predominant genital mycoplasma detected, with resistance to several antimicrobial agents, particularly fluoroquinolones. As species-level identification, clinical outcome assessment, and systematic follow-up data were limited, these findings should be viewed as descriptive local surveillance data rather than direct treatment-guiding evidence.
trial registrationNot applicable. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.